EUVIMEDEUVIMED entdecken
Open Access

Site-specific outcomes and genomics in metastatic pancreatic ductal adenocarcinoma

Mahmoud Yousef, Saikat Chowdhury, Sali Albarouki, Ahmed Elhariri, Guglielmo Vetere, Sacha El Khoury, Mohammad Fanaeian, Abdelrahman Yousef, Ashwathy Balachandran Pillai, Kristin Alfaro-Munoz, Mark Knafl, Paul Roy und 23 weitere

The Oncologist · 05.11.2026 · 31 (12)

DOI: 10.1093/oncolo/oyag423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 20.10.2026. Verfasst von Mahmoud Yousef und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Genomics, Liver Neoplasms. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Center Support Grant, University of Texas MD Anderson Cancer Center startup grant awarded to Dan Zhao and by the Col.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical and molecular features of pancreatic adenocarcinoma (PDAC) according to involved metastatic sites have not been well characterized. Materials and methods We used the Foundry platform to query information for patients with metastatic PDAC at MD Anderson Cancer Center. Involved metastatic sites were extracted using natural language processing from imaging reports and verified by chart reviews. Overall survival (OS) and next-generation sequencing (NGS) data were analyzed.

Results

In a cohort of 1095 patients (median overall survival [OS]: 22.8 months), lung-only metastasis was associated with longer median OS (57.6 months, P < .0001). Patients with metastases not involving the liver had OS of 41.3 months, while liver-only (19.5 months) and multiple sites including liver (19.3 months) had the poorest survival. TP53 mutation rates were higher in liver-involved groups (84-85%) vs lung-only (73%) and non-liver metastases (67%, P < .0001). Lower rates of GNAS mutations were detected in liver-only (5%) and liver-involved (2%) cases, and higher in lung-only (8%) and non-liver (10%, P < .01). The frequency of KRAS mutation and mutant allele distribution were not significantly different in tissue-based NGS. However, in liquid biopsy analysis (n = 240), lung-only metastasis showed the lowest mutation detection (50%), TP53 (23%) and KRAS (10%), compared to liver-only detection rates of 65%, 46%, and 52%, respectively (P values: .009, .02, <.001).

Conclusions

Patients with PDAC without liver metastasis have significantly improved OS and lower rates of TP53 mutation. Patients with lung-only metastasis had longer OS, a lower liquid-biopsy positivity rate, and a lower rate of KRAS detection by liquid biopsy; because liquid biopsy may under-detect KRAS in lung-only disease, tumor-tissue sequencing should be prioritized in these patients as KRAS-directed therapies emerge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsGenomicsLiver NeoplasmsHumansFemaleMaleAgedMiddle AgedMutationNeoplasm MetastasisTumor Suppressor Protein p53High-Throughput Nucleotide SequencingProto-Oncogene Proteins p21(ras)Adult

Stichwörter der Autor:innen

liver metastasislung metastasismolecularoutcomepancreatic adenocarcinoma

Substanzen

KRAS protein, humanTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX 77030, United States.
  • Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Internal Medicine, University of New Mexico Hospital, Albuquerque, NM 87131, United States.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Enterprise Data Engineering and Analytics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Jason Willis, Rebecca A Snyder, Naruhiko Ikoma, Dan Zhao

Förderung

  • NCI NIH HHS
  • Cancer Center Support Grant
  • University of Texas MD Anderson Cancer Center startup grant awarded to Dan Zhao and by the Col
  • National Cancer Institute

Zitieren

APA

Yousef, M., Chowdhury, S., Albarouki, S., Elhariri, A., Vetere, G., El Khoury, S., Fanaeian, M., Yousef, A., Balachandran Pillai, A., Alfaro-Munoz, K., Knafl, M., Roy, P., Hurd, M. W., Smaglo, B. G., Wolff, R. A., Pant, S., Willis, J., Huey, R., Overman, M. J., …, & Zhao, D. (2026). Site-specific outcomes and genomics in metastatic pancreatic ductal adenocarcinoma. The Oncologist, 31(12). https://doi.org/10.1093/oncolo/oyag423

Vancouver

Yousef M, Chowdhury S, Albarouki S, Elhariri A, Vetere G, El Khoury S, et al. Site-specific outcomes and genomics in metastatic pancreatic ductal adenocarcinoma. The Oncologist. 2026;31(12). doi:10.1093/oncolo/oyag423

BibTeX
@article{Yousef2026,
  author = {Yousef, Mahmoud and Chowdhury, Saikat and Albarouki, Sali and Elhariri, Ahmed and Vetere, Guglielmo and El Khoury, Sacha and Fanaeian, Mohammad and Yousef, Abdelrahman and Balachandran Pillai, Ashwathy and Alfaro-Munoz, Kristin and Knafl, Mark and Roy, Paul and Hurd, Mark W and Smaglo, Brandon G and Wolff, Robert A and Pant, Shubham and Willis, Jason and Huey, Ryan and Overman, Michael J and Lopez, Camila and Chen, Anthony and Ludmir, Ethan B and Koay, Eugene J and Snyder, Rebecca A and Tzeng, Ching-Wei and Kim, Michael P and Ikoma, Naruhiko and Maxwell, Jessica E and Wang, Huamin and Maitra, Anirban and Katz, Matthew H G and Chen, Yang and Ying, Haoqiang and Shen, John Paul and Zhao, Dan},
  title = {Site-specific outcomes and genomics in metastatic pancreatic ductal adenocarcinoma},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {12},
  doi = {10.1093/oncolo/oyag423}
}
Kostenlos starten →